- Home
- XOMA vs PROC Comparison
XOMA vs PROC Comparison
Compare XOMA & PROC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMA
- PROC
- Stock Information
- Founded
- XOMA 1981
- PROC 1976
- Country
- XOMA United States
- PROC Luxembourg
- Employees
- XOMA N/A
- PROC N/A
- Industry
- XOMA Biotechnology: Pharmaceutical Preparations
- PROC Biotechnology: Pharmaceutical Preparations
- Sector
- XOMA Health Care
- PROC Health Care
- Exchange
- XOMA Nasdaq
- PROC Nasdaq
- Market Cap
- XOMA 320.8M
- PROC 203.1M
- IPO Year
- XOMA N/A
- PROC N/A
- Fundamental
- Price
- XOMA $28.59
- PROC $1.90
- Analyst Decision
- XOMA Strong Buy
- PROC
- Analyst Count
- XOMA 2
- PROC 0
- Target Price
- XOMA $78.50
- PROC N/A
- AVG Volume (30 Days)
- XOMA 18.9K
- PROC 9.8K
- Earning Date
- XOMA 11-05-2024
- PROC 11-12-2024
- Dividend Yield
- XOMA N/A
- PROC N/A
- EPS Growth
- XOMA N/A
- PROC N/A
- EPS
- XOMA N/A
- PROC 0.52
- Revenue
- XOMA $15,239,000.00
- PROC $414,096,000.00
- Revenue This Year
- XOMA $456.45
- PROC $5.54
- Revenue Next Year
- XOMA $29.84
- PROC $8.54
- P/E Ratio
- XOMA N/A
- PROC $3.68
- Revenue Growth
- XOMA 277.95
- PROC N/A
- 52 Week Low
- XOMA $14.27
- PROC $1.68
- 52 Week High
- XOMA $30.50
- PROC $4.95
- Technical
- Relative Strength Index (RSI)
- XOMA 53.55
- PROC 43.98
- Support Level
- XOMA $28.66
- PROC $1.77
- Resistance Level
- XOMA $30.50
- PROC $2.06
- Average True Range (ATR)
- XOMA 1.07
- PROC 0.11
- MACD
- XOMA 0.21
- PROC -0.02
- Stochastic Oscillator
- XOMA 55.56
- PROC 25.86
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
About PROC Procaps Group S.A.
Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.